Privigen (IVIG) is supported by multiple clinical trials and evidence summaries for immune-mediated myopathies, including polymyositis. Below is a summary of key evidence, focusing on clinical trial data and outcomes. pmc.ncbi.nlm.nih+3

Overview of Evidence

• IVIG, including Privigen, is supported for refractory polymyositis and dermatomyositis through case series, open-label studies, and systematic reviews. ameripharmaspecialty+1
• The body of evidence includes moderate-sized open-label trials, individual patient reports, and guideline endorsements. droracle+1
• While Privigen is FDA-approved for other conditions like CIDP, its use in myositis syndromes is based on extrapolated IVIG data. privigen

Key Clinical Trials and Studies

Phase 2 Open-Label Study – Privigen Monotherapy (NTR6160) pmc.ncbi.nlm.nih

• Population: 20 adults with newly diagnosed idiopathic inflammatory myopathy (including PM), biopsy-proven.
• Design: Loading dose 2 g/kg, followed by two maintenance doses (1 g/kg every 3 weeks).
• Outcomes:
  • 42% experienced at least moderate improvement by 9 weeks (ACR/EULAR TIS criteria).
  • Most responders improved by week 3.
  • Non-responders discontinued early or received rescue medication.
• Safety: Three serious AEs; one pulmonary embolism.
• Conclusion: IVIG (Privigen) monotherapy led to rapid, moderate improvement in nearly half of new-onset inflammatory myopathy cases; suggested further investigation for optimal regimen.

Systematic Reviews and Case Series uhcprovider+2

• Findings:
  • Reviews show ~70% of patients with refractory PM/DM respond to IVIG, with improved muscle strength and CK reduction.
  • Response rates and efficacy generally maintained for up to 3 years.
• Barriers: Cost and product access noted as important limitations.

Additional Case Reports ameripharmaspecialty+1

• Individual reports and smaller series highlight improved muscle strength, swallowing, and even lung function in resistant polymyositis treated with IVIG.
• Evidence supports use for polymyositis-associated lung involvement.

Ongoing and Recent Studies clinicaltrials

• Phase II trial completed in 2025 enrolling patients with polymyositis or dermatomyositis included IVIG (Privigen) arms; details pending, but confirms continued investigation and modern interest.

Summary Table: Key Clinical Evidence

Clinical trial and review data confirm Privigen (IVIG) is safe and effective in many patients with polymyositis, and large, randomized controlled trials continue to be developed. clinicaltrials+4

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC8023983/
2. https://ameripharmaspecialty.com/ivig/considering-ivig-for-polymyositis-heres-what-you-need-to-know/
3. https://www.droracle.ai/articles/256932/paula-torres-is
4. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/immune-globulin-ivig-scig.pdf
5. https://www.privigen.com/hcp/efficacy-and-safety
6. https://clinicaltrials.gov/study/NCT07122648
7. https://www.droracle.ai/articles/162992/what-is-the-privigen-ivig-dosage-for-dermatomyositis
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4124644/
9. https://www.droracle.ai/articles/168619/was-immune-globulin
10. https://www.the-rheumatologist.org/article/myositis-management-clinical-trials-provide-new-insights-into-treatment-options/3/
11. https://www.fda.gov/media/107550/download
12. https://www.myositis.org/wp-content/uploads/2018/01/IVIG-in-Myositis-2014-8-21-2.pdf
13. https://pubmed.ncbi.nlm.nih.gov/23781960/
14. https://clinicaltrials.gov/study/NCT01184846
15. https://www.myositis.org/wp-content/uploads/2018/01/Evolving-Applications-of-IVIG-in-Myositis-FINAL.pdf
16. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00411-X/fulltext
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2697917/
18. https://www.rarediseaseadvisor.com/therapies/privigen/
19. https://www.criteria.blood.gov.au/MedicalCondition/View/2578
20. https://newsroom.csl.com/2010-10-07-Privigen-Demonstrates-Efficacy-and-Tolerability-Among-Patients-With-Various-Immunodeficiencies,-Data-Show